Skip to main content
Top
Published in: BMC Geriatrics 1/2018

Open Access 01-12-2018 | Research Article

Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden

Authors: Iris Zahirovic, Gustav Torisson, Carina Wattmo, Elisabet Londos

Published in: BMC Geriatrics | Issue 1/2018

Login to get access

Abstract

Background

Elderly persons with a dementia diagnosis often suffer from different neuropsychiatric symptoms (NPS) such as delusions, hallucinations, depression, anxiety, irritability and agitation. Currently, the medical treatment for NPS consists mostly of psychotropic medication such as hypnotics/sedatives, anxiolytics and antipsychotics. In elderly persons with dementia, usage of antipsychotics is less appropriate because of the risk of side effects such as parkinsonism, rapid cognitive decline, cerebrovascular events and finally mortality. Furthermore, elderly persons with dementia with Lewy bodies (DLB) are often hypersensitive to antipsychotics with numerous serious adverse events such as somnolence, sedation, extra-pyramidal symptoms, delirium and increased mortality. The aim of this study was to investigate the usage of psychotropics with a focus on antipsychotics and anti-dementia medication (according to the Anatomical Therapeutic Chemical Classification System) in elderly persons with clinical signs of DLB living in dementia nursing homes (NHs) in Sweden.

Methods

Between 2012 and 2013, we applied a specially designed questionnaire that covered the clinical DLB features according to the consensus criteria of DLB. We also collected computerized medical lists from the Swedish National Medication Dispensing System from the same period. All dementia NHs (n = 40) in Malmö, the third largest city in Sweden, were covered. Of 650 eligible residents, 610 (94%) were included with 576 medical lists. The mean age was 86 years and 76% were women.

Results

Treatment with antipsychotics was seen in 22% of residents, hypnotics/sedatives in 41%, antidepressants in 50% and anxiolytics in 58%. We also found an increasing usage of antipsychotics from 25% to 43% in residents with the increasing number of DLB features. Anti-dementia medications were found in 45% of the elderly with a dementia diagnosis. However, residents with two or more DLB features had less anti-dementia medication (37%) than the rest of the dementia-diagnosed NH residents (62–69%).

Conclusions

Residents with 2–4 DLB clinical features in Swedish NHs receive an unfavourable medical treatment with high antipsychotic usage and insufficient anti-dementia medication. These findings show the importance of identifying elderly persons with DLB features more effectively and improving the collaboration with nursing care to provide better medical prescription.
Literature
1.
go back to reference Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–7.CrossRefPubMedPubMedCentral Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–7.CrossRefPubMedPubMedCentral
2.
go back to reference Wimo A, Jonsson L, Bond J, Prince M, Winblad B, Alzheimer DI. The worldwide economic impact of dementia 2010. Alzheimer's dement. 2013;9(1):1–11. e3CrossRef Wimo A, Jonsson L, Bond J, Prince M, Winblad B, Alzheimer DI. The worldwide economic impact of dementia 2010. Alzheimer's dement. 2013;9(1):1–11. e3CrossRef
3.
go back to reference Mollenhauer B, Forstl H, Deuschl G, Storch A, Oertel W, Lewy TC. Body and parkinsonian dementia: common, but often misdiagnosed conditions. Deutsches Arzteblatt international. 2010;107(39):684–91.PubMedPubMedCentral Mollenhauer B, Forstl H, Deuschl G, Storch A, Oertel W, Lewy TC. Body and parkinsonian dementia: common, but often misdiagnosed conditions. Deutsches Arzteblatt international. 2010;107(39):684–91.PubMedPubMedCentral
4.
go back to reference Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005;34(6):561–6.CrossRefPubMed Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005;34(6):561–6.CrossRefPubMed
5.
go back to reference Selbaek G, Kirkevold O, Engedal K. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes--a 12-month follow-up study. A J Geriatr Psychiatry. 2008;16(7):528–36.CrossRef Selbaek G, Kirkevold O, Engedal K. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes--a 12-month follow-up study. A J Geriatr Psychiatry. 2008;16(7):528–36.CrossRef
6.
go back to reference Liperoti R, Pedone C, Corsonello A. Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Curr Neuropharmacol. 2008;6(2):117–24.CrossRefPubMedPubMedCentral Liperoti R, Pedone C, Corsonello A. Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Curr Neuropharmacol. 2008;6(2):117–24.CrossRefPubMedPubMedCentral
7.
go back to reference McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65(12):1863–72.CrossRefPubMed McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65(12):1863–72.CrossRefPubMed
8.
go back to reference McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. The Lancet Neurology. 2004;3(1):19–28.CrossRefPubMed McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. The Lancet Neurology. 2004;3(1):19–28.CrossRefPubMed
9.
go back to reference McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 2017;89(1):88–100.CrossRefPubMedPubMedCentral McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 2017;89(1):88–100.CrossRefPubMedPubMedCentral
10.
go back to reference Fujimi K, Sasaki K, Noda K, Wakisaka Y, Tanizaki Y, Matsui Y, et al. Clinicopathological outline of dementia with Lewy bodies applying the revised criteria: the Hisayama study. Brain Pathol. 2008;18(3):317–25.CrossRefPubMed Fujimi K, Sasaki K, Noda K, Wakisaka Y, Tanizaki Y, Matsui Y, et al. Clinicopathological outline of dementia with Lewy bodies applying the revised criteria: the Hisayama study. Brain Pathol. 2008;18(3):317–25.CrossRefPubMed
11.
go back to reference Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci. 2006;7(6):492–500.CrossRefPubMed Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci. 2006;7(6):492–500.CrossRefPubMed
12.
go back to reference Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335–41.CrossRefPubMed Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335–41.CrossRefPubMed
13.
go back to reference Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am J Geriatr Psychiatry. 2014;22(4):321–31.CrossRefPubMed Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am J Geriatr Psychiatry. 2014;22(4):321–31.CrossRefPubMed
14.
go back to reference Rongve A, Vossius C, Nore S, Testad I, Aarsland D. Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer's dementia. International journal of geriatric psychiatry. 2014;29(4):392–8.CrossRefPubMed Rongve A, Vossius C, Nore S, Testad I, Aarsland D. Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer's dementia. International journal of geriatric psychiatry. 2014;29(4):392–8.CrossRefPubMed
15.
go back to reference Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775–86.CrossRefPubMed Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775–86.CrossRefPubMed
16.
go back to reference Schneider LS, Dagerman K, Insel PS. Efficacy and Adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.CrossRefPubMed Schneider LS, Dagerman K, Insel PS. Efficacy and Adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.CrossRefPubMed
17.
go back to reference Swanberg MM, Cummings JL. Benefit-risk considerations in the treatment of dementia with Lewy bodies. Drug Saf. 2002;25(7):511–23.CrossRefPubMed Swanberg MM, Cummings JL. Benefit-risk considerations in the treatment of dementia with Lewy bodies. Drug Saf. 2002;25(7):511–23.CrossRefPubMed
18.
go back to reference McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305(6855):673–8.CrossRefPubMedPubMedCentral McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305(6855):673–8.CrossRefPubMedPubMedCentral
19.
go back to reference Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. The Lancet Neurology. 2009;8(7):613–8.CrossRefPubMed Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. The Lancet Neurology. 2009;8(7):613–8.CrossRefPubMed
20.
go back to reference FDA: 2008 Information on Conventional Antipsychotics [Internet]. U.S. Food and Drug Administration. 6/16/2008. FDA: 2008 Information on Conventional Antipsychotics [Internet]. U.S. Food and Drug Administration. 6/16/2008.
21.
go back to reference Welfare TSNBoHa. The usage of antipsychotic medication according to Swedish National Board of Health and Welfare "Användning av antipsykotiska läkemedel hos äldre". 2015. Welfare TSNBoHa. The usage of antipsychotic medication according to Swedish National Board of Health and Welfare "Användning av antipsykotiska läkemedel hos äldre". 2015.
22.
go back to reference EMEA EMA. European Medicines Agency: CHMP assessment report on conventional antipsychotics. Procedure under Article 5(3) of Regulation (EC) No 726/2004. 2004;590557/2008. EMEA EMA. European Medicines Agency: CHMP assessment report on conventional antipsychotics. Procedure under Article 5(3) of Regulation (EC) No 726/2004. 2004;590557/2008.
23.
go back to reference Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627–32.CrossRefPubMedPubMedCentral Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627–32.CrossRefPubMedPubMedCentral
24.
go back to reference Guthrie B, Clark SA, Reynish EL, McCowan C, Morales DR. Differential impact of two risk communications on antipsychotic prescribing to people with dementia in Scotland: segmented regression time series analysis 2001-2011. PLoS One. 2013;8(7):e68976.CrossRefPubMedPubMedCentral Guthrie B, Clark SA, Reynish EL, McCowan C, Morales DR. Differential impact of two risk communications on antipsychotic prescribing to people with dementia in Scotland: segmented regression time series analysis 2001-2011. PLoS One. 2013;8(7):e68976.CrossRefPubMedPubMedCentral
25.
go back to reference Giron MS, Forsell Y, Bernsten C, Thorslund M, Winblad B, Fastbom J. Psychotropic drug use in elderly people with and without dementia. International journal of geriatric psychiatry. 2001;16(9):900–6.CrossRefPubMed Giron MS, Forsell Y, Bernsten C, Thorslund M, Winblad B, Fastbom J. Psychotropic drug use in elderly people with and without dementia. International journal of geriatric psychiatry. 2001;16(9):900–6.CrossRefPubMed
26.
go back to reference Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio RV, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry. 2011;68(2):190–7.CrossRefPubMed Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio RV, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry. 2011;68(2):190–7.CrossRefPubMed
27.
go back to reference Bergman A, Olsson J, Carlsten A, Waern M, Fastbom J. Evaluation of the quality of drug therapy among elderly patients in nursing homes. Scand J Prim Health Care. 2007;25(1):9–14.CrossRefPubMedPubMedCentral Bergman A, Olsson J, Carlsten A, Waern M, Fastbom J. Evaluation of the quality of drug therapy among elderly patients in nursing homes. Scand J Prim Health Care. 2007;25(1):9–14.CrossRefPubMedPubMedCentral
28.
go back to reference Zakarias JK, Jensen-Dahm C, Norgaard A, Stevnsborg L, Gasse C, Andersen BG, et al. Geographical variation in antipsychotic drug use in elderly patients with dementia: a Nationwide study. Journal of Alzheimer's disease: JAD. 2016;54(3):1183–92.CrossRefPubMed Zakarias JK, Jensen-Dahm C, Norgaard A, Stevnsborg L, Gasse C, Andersen BG, et al. Geographical variation in antipsychotic drug use in elderly patients with dementia: a Nationwide study. Journal of Alzheimer's disease: JAD. 2016;54(3):1183–92.CrossRefPubMed
29.
go back to reference Zahirovic I, Wattmo C, Torisson G, Minthon L, Londos E. Prevalence of dementia with Lewy body symptoms: a cross-sectional study in 40 Swedish nursing homes. J Am Med Dir Assoc. 2016;17(8):706–11.CrossRefPubMed Zahirovic I, Wattmo C, Torisson G, Minthon L, Londos E. Prevalence of dementia with Lewy body symptoms: a cross-sectional study in 40 Swedish nursing homes. J Am Med Dir Assoc. 2016;17(8):706–11.CrossRefPubMed
30.
go back to reference The Swedish National Board of Health and Welfare. National Guidelines for Health and Social Care for demented elderly 2016/Nationella riktlinjer för vård och omsorg vid demenssjukdom. 2016. The Swedish National Board of Health and Welfare. National Guidelines for Health and Social Care for demented elderly 2016/Nationella riktlinjer för vård och omsorg vid demenssjukdom. 2016.
32.
go back to reference Dunkel M, Gunther S, Ahmed J, Wittig B, Preissner R. SuperPred: drug classification and target prediction. Nucleic Acids Res. 2008;36(Web Server):W55–9.CrossRefPubMedPubMedCentral Dunkel M, Gunther S, Ahmed J, Wittig B, Preissner R. SuperPred: drug classification and target prediction. Nucleic Acids Res. 2008;36(Web Server):W55–9.CrossRefPubMedPubMedCentral
33.
go back to reference Aarsland D, Rongve A, Nore SP, Skogseth R, Skulstad S, Ehrt U, et al. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord. 2008;26(5):445–52.CrossRefPubMed Aarsland D, Rongve A, Nore SP, Skogseth R, Skulstad S, Ehrt U, et al. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord. 2008;26(5):445–52.CrossRefPubMed
34.
go back to reference Bostrom F, Jonsson L, Minthon L, Londos E. Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):150–4.CrossRefPubMed Bostrom F, Jonsson L, Minthon L, Londos E. Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):150–4.CrossRefPubMed
35.
go back to reference Heidebrink JL. Is dementia with Lewy bodies the second most common cause of dementia? J Geriatr Psychiatry Neurol. 2002;15(4):182–7.CrossRefPubMed Heidebrink JL. Is dementia with Lewy bodies the second most common cause of dementia? J Geriatr Psychiatry Neurol. 2002;15(4):182–7.CrossRefPubMed
36.
go back to reference Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Nursing home placement in the donepezil and Memantine in moderate to severe Alzheimer's disease (DOMINO-AD) trial: secondary and post-hoc analyses. The Lancet Neurology. 2015;14(12):1171–81.CrossRefPubMed Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Nursing home placement in the donepezil and Memantine in moderate to severe Alzheimer's disease (DOMINO-AD) trial: secondary and post-hoc analyses. The Lancet Neurology. 2015;14(12):1171–81.CrossRefPubMed
37.
go back to reference Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007;164(10):1568–76. quiz 623CrossRefPubMed Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007;164(10):1568–76. quiz 623CrossRefPubMed
38.
go back to reference Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological Management of Lewy Body Dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(8):731–42.CrossRefPubMed Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological Management of Lewy Body Dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(8):731–42.CrossRefPubMed
39.
go back to reference Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM. The effect of quetiapine in psychotic parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol. 2006;253(2):171–5.CrossRefPubMed Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM. The effect of quetiapine in psychotic parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol. 2006;253(2):171–5.CrossRefPubMed
40.
go back to reference Kurlan R, Cummings J, Raman R, Thal L. Alzheimer's disease cooperative study G. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356–63.CrossRefPubMed Kurlan R, Cummings J, Raman R, Thal L. Alzheimer's disease cooperative study G. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356–63.CrossRefPubMed
41.
go back to reference Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168(8):831–9.CrossRefPubMedPubMedCentral Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168(8):831–9.CrossRefPubMedPubMedCentral
42.
go back to reference Vasudev A, Shariff SZ, Liu K, Burhan AM, Herrmann N, Leonard S, et al. Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004-2013. Am J Geriatr Psychiatry. 2015;23(12):1259–69.CrossRefPubMed Vasudev A, Shariff SZ, Liu K, Burhan AM, Herrmann N, Leonard S, et al. Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004-2013. Am J Geriatr Psychiatry. 2015;23(12):1259–69.CrossRefPubMed
43.
go back to reference Agency MP. Läkemedelsbehandling och bemötande vid Beteendemässiga och Psykiatriska Symptom vid Demenssjukdom-BPSD. 2008;5:15–24. Agency MP. Läkemedelsbehandling och bemötande vid Beteendemässiga och Psykiatriska Symptom vid Demenssjukdom-BPSD. 2008;5:15–24.
44.
go back to reference Kamble P, Chen H, Sherer J, Aparasu RR. Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother. 2008;6(4):187–97.CrossRefPubMed Kamble P, Chen H, Sherer J, Aparasu RR. Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother. 2008;6(4):187–97.CrossRefPubMed
45.
go back to reference Snowdon J, Galanos D, Vaswani D. Patterns Of psychotropic medication use in nursing homes: surveys in Sydney, allowing comparisons over time and between countries. International psychogeriatrics / IPA. 2011;23(9):1520–5.CrossRef Snowdon J, Galanos D, Vaswani D. Patterns Of psychotropic medication use in nursing homes: surveys in Sydney, allowing comparisons over time and between countries. International psychogeriatrics / IPA. 2011;23(9):1520–5.CrossRef
46.
47.
go back to reference Cummings J, Lai TJ, Hemrungrojn S, Mohandas E, Yun Kim S, Nair G, et al. Role of donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's disease and dementia with Lewy bodies. CNS neuroscience & therapeutics. 2016;22(3):159–66.CrossRef Cummings J, Lai TJ, Hemrungrojn S, Mohandas E, Yun Kim S, Nair G, et al. Role of donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's disease and dementia with Lewy bodies. CNS neuroscience & therapeutics. 2016;22(3):159–66.CrossRef
Metadata
Title
Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden
Authors
Iris Zahirovic
Gustav Torisson
Carina Wattmo
Elisabet Londos
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2018
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-018-0740-4

Other articles of this Issue 1/2018

BMC Geriatrics 1/2018 Go to the issue